Discounted Cash Flow (DCF) Analysis Levered
Bionano Genomics, Inc. (BNGO)
$0.794
+0.06 (+8.44%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.33 | -0.06 | 4.66 | -0.82 | -2.41 | 2.84 | 3.79 | 5.06 | 6.76 | 9.03 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -20.28 | -29.59 | -33.66 | -72.75 | -127.22 | -127.72 | -170.64 | -227.99 | -304.62 | -406.99 |
Weighted Average Cost Of Capital
| Share price | $ 0.794 |
|---|---|
| Beta | 2.246 |
| Diluted Shares Outstanding | 289.21 |
| Cost of Debt | |
| Tax Rate | -1.44 |
| After-tax Cost of Debt | 2.55% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 14.290 |
| Total Debt | 11.67 |
| Total Equity | 229.63 |
| Total Capital | 241.30 |
| Debt Weighting | 4.84 |
| Equity Weighting | 95.16 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
| Capital Expenditure | -0.33 | -0.06 | 4.66 | -0.82 | -2.41 | 2.84 | 3.79 | 5.06 | 6.76 | 9.03 |
| Free Cash Flow | -20.28 | -29.59 | -33.66 | -72.75 | -127.22 | -127.72 | -170.64 | -227.99 | -304.62 | -406.99 |
| WACC | ||||||||||
| PV LFCF | -112.31 | -131.95 | -155.03 | -182.14 | -213.99 | |||||
| SUM PV LFCF | -795.42 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 13.72 |
| Free cash flow (t + 1) | -415.13 |
| Terminal Value | -3,542.09 |
| Present Value of Terminal Value | -1,862.41 |
Intrinsic Value
| Enterprise Value | -2,657.83 |
|---|---|
| Net Debt | 6.58 |
| Equity Value | -2,664.41 |
| Shares Outstanding | 289.21 |
| Equity Value Per Share | -9.21 |